login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
EVOLUS INC (EOLS) Stock News
NASDAQ:EOLS -
US30052C1071
-
Common Stock
7.66
USD
+0.15 (+2%)
Last: 9/5/2025, 8:10:06 PM
7.6204
USD
-0.04 (-0.52%)
After Hours:
9/5/2025, 8:10:06 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EOLS Latest News, Press Relases and Analysis
All
Press Releases
12 days ago - By: Evolus
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
17 days ago - By: Evolus
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
a month ago - By: Evolus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
a month ago - By: Benzinga
A Look Ahead: Evolus's Earnings Forecast
a month ago - By: The Motley Fool
Evolus (EOLS) Q2 Revenue Rises 4%
a month ago - By: Zacks Investment Research
- Mentions:
SRDX
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
a month ago - By: Evolus
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
a month ago - By: Evolus
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
a month ago - By: Zacks Investment Research
- Mentions:
RMD
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline
2 months ago - By: Evolus
Evolus to Report Second Quarter Financial Results on August 5, 2025
2 months ago - By: Evolus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Evolus
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
3 months ago - By: Evolus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Evolus
Evolysse™ Recognized in 2025 Shape Skin Awards
3 months ago - By: Evolus
Evolus Announces Departure of its Chief Financial Officer
4 months ago - By: Evolus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
4 months ago - By: Evolus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Yahoo Finance
- Mentions:
VZ
DHI
CMG
Evolus, Inc. (EOLS): A Bull Case Theory
4 months ago - By: Zacks Investment Research
- Mentions:
ALUR
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
4 months ago - By: Evolus
Evolus Reports First Quarter 2025 Results
4 months ago - By: Evolus
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
4 months ago - By: Zacks Investment Research
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
5 months ago - By: Evolus
Evolus to Report First Quarter Financial Results on May 7, 2025
Please enable JavaScript to continue using this application.